Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMRECC2)

• Drug Name: YH006 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Aggressive cancer	2A00-2F9Z	Investigative	[1]

• Cross-matching ID: TTD Drug ID: DMRECC2

Molecule-Related Drug Atlas

Drug(s) Targeting Cytotoxic T-lymphocyte protein 4 (CTLA-4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ipilimumab	DMJTIYK	Melanoma	2C30	Approved	[2]
Tremelimumab	DMOQ9H1	Hepatocellular carcinoma	2C12.02	Approved	[3]
KN046	DMSDBPG	Non-small-cell lung cancer	2C25.Y	Phase 3	[4]
AK04	DMU7K86	Actinic keratosis	EK90.0	Phase 3	[5]
AK104	DMXJ8Z4	Cervical cancer	2C77.0	Phase 2	[6]
Lorigerlimab	DM2E8Z5	Prostate cancer	2C82.0	Phase 2	[7]
Vudalimab	DMSEEI0	Prostate cancer	2C82.0	Phase 2	[8]
AGEN1884	DMAP5B4	Cervical cancer	2C77.0	Phase 1/2	[9]
BMS-986288	DMM10J4	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[10]
MK-1308	DM25QKC	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[11]

Drug(s) Targeting OX40L receptor (CD134)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Rocatinlimab	DMG1U5K	Atopic dermatitis	EA80	Phase 3	[12]
GBR 830	DM2VO9T	Atopic dermatitis	EA80	Phase 2	[13]
PF-04518600	DMZMUIL	Solid tumour/cancer	2A00-2F9Z	Phase 2	[14]
INCAGN01949	DMK7OHI	Advanced malignancy	2A00-2F9Z	Phase 2	[15]
INCAGN1949	DM7OE3X	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[9]
TAK-252	DM1AKNI	Solid tumour/cancer	2A00-2F9Z	Phase 1	[16]
Anti-OX40 mab	DMFZ52G	Prostate cancer	2C82.0	Phase 1	[17]
MEDI0562	DMYVBU6	Solid tumour/cancer	2A00-2F9Z	Phase 1	[14]
BGB-A445	DMQMEDH	Solid tumour/cancer	2A00-2F9Z	Phase 1	[18]
YH002	DMWVRHD	Aggressive cancer	2A00-2F9Z	Phase 1	[19]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cytotoxic T-lymphocyte protein 4 (CTLA-4)	TTI2S1D	CTLA4_HUMAN	Not Available	[1]
OX40L receptor (CD134)	TTL31H0	TNR4_HUMAN	Not Available	[1]

References

• [1] Clinical pipeline report, company report or official report of Biocytogen
• [2] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2743).
• [4] Clinical pipeline report, company report or official report of Alphamab Oncology.
• [5] A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104-202 study). Lung Cancer. 2023 Oct;184:107355.
• [6] Clinical pipeline report, company report or official report of Akeso Biopharma.
• [7] Clinical pipeline report, company report or official report of MacroGenics
• [8] Clinical pipeline report, company report or official report of Xencor
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] Clinical pipeline report, company report or official report of CytomX Therapeutics.
• [11] Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer. Ann Oncol. 2021 Mar;32(3):395-403.
• [12] An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study. Lancet. 2023 Jan 21;401(10372):204-214.
• [13] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [14] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [15] Sequential therapy with INCAGN01949 followed by ipilimumab and nivolumab in two patients with advanced ovarian carcinoma. Gynecol Oncol Rep. 2020 Oct 1;34:100655.
• [16] Clinical pipeline report, company report or official report of Shattuck Labs.
• [17] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1873).
• [18] Clinical pipeline report, company report or official report of BeiGene.
• [19] Clinical pipeline report, company report or official report of Biocytogen